Pay in 4 interest-free payments of $7.00 Learn more
![glp 1 mimetic example A Brief Review of Incretin Mimetics Intended for the Management of Diabetes and Associated Comorbidities[v1] Glucagon-like peptide-1 (GLP-1) receptor agonists](https://www.preprints.org/frontend/picture/ms_xml/manuscript/28233dba55c7b404c1a8e0b10dd5de8e/preprints-107031-g002.png)
Ships within 48 hours · Estimated delivery Nov 7 - Nov 12
Mayo Clinic Proceedings, Volume 77, Issue 8, 754 759 Perricone C, De Carolis C, Perricone R
![glp 1 mimetic example A Brief Review of Incretin Mimetics Intended for the Management of Diabetes and Associated Comorbidities[v1] Glucagon-like peptide-1 (GLP-1) receptor agonists](https://ars.els-cdn.com/content/image/1-s2.0-S1043661822004960-ga1.jpg)
The hormone is necessary to lower your blood sugar (glucose) level
Or maybe youve been quietly researching on your phone at 2 a.m., wondering if these weight loss injections could finally be the thing that works for you
![glp 1 mimetic example A Brief Review of Incretin Mimetics Intended for the Management of Diabetes and Associated Comorbidities[v1] Glucagon-like peptide-1 (GLP-1) receptor agonists](https://lookaside.instagram.com/seo/google_widget/crawler/?media_id=2552890173768012247)
The trials' endpointsthe outcomes measured to determine the drugs' main effectsalso did not consider mental health outcomes
![glp 1 mimetic example A Brief Review of Incretin Mimetics Intended for the Management of Diabetes and Associated Comorbidities[v1] Glucagon-like peptide-1 (GLP-1) receptor agonists](https://lookaside.fbsbx.com/lookaside/crawler/media/?media_id=1798477454746863)
doi: 10.1038/oby.2006.121 97 LaferrreBAbrahamCRussellCDBowersCY
![glp 1 mimetic example A Brief Review of Incretin Mimetics Intended for the Management of Diabetes and Associated Comorbidities[v1] Glucagon-like peptide-1 (GLP-1) receptor agonists](https://www.cell.com/cms/10.1016/j.cmet.2025.10.014/asset/fb73a5bb-243a-4770-bdc1-8f9ade3982d2/main.assets/fx1_lrg.jpg)
Patient and insurer spending on GLP-1s jumped from $13.7 billion in 2018 to $71.7 billion in 2023, a financial surge that generated headlines implying innovation rather than the scaling of proven science
![glp 1 mimetic example A Brief Review of Incretin Mimetics Intended for the Management of Diabetes and Associated Comorbidities[v1] Glucagon-like peptide-1 (GLP-1) receptor agonists](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41392-024-01931-z/MediaObjects/41392_2024_1931_Fig5_HTML.png)
US$ 25.28
US$ 29.76
US$ 29.22
US$ 24.16
